Back
Status filter :


RESET SEARCH AND FILTERS
Gastro-intestinal system
Gastro-intestinal system / Inflammatory bowel disease
  adalimumab Hospital only NICE TA187
NICE TA329
NICE TA199
NICE TA195
NICE TA375
NICE TA715
NICE TA383
NICE TA392
NICE TA146
NICE TA460
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  Solution for injection
Humira (AbbVie Ltd) Hospital only
ADALIMUMAB

Dose escalation of Adalimumab is approved for Crohn's disease and ulcerative colitis

  azathioprine Shared care guideline
A formal Shared Care Guideline (SCG) may be available

Happy to prescribe

If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. 

Unhappy to prescribe

If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. 

  balsalazide sodium Specialist knowledge/initiation
  beclometasone dipropionate Hospital only
Us of beclometasone modified release tablets

Oral beclometasone modified release tablets should only be used as second-line option (after prednisolone tablets) for the treatment of mild or moderate ulcerative colitis in active phase of left-sided or extensive UC. This would be used as add-on therapy to 5-ASA containing drugs in patients who are non-responders to 5-ASA therapy. The full 4 week therapy cycle must be prescribed by secondary care.

  Modified-release tablet
Clipper (Chiesi Ltd) Hospital only
Us of beclometasone modified release tablets

Oral beclometasone modified release tablets should only be used as second-line option (after prednisolone tablets) for the treatment of mild or moderate ulcerative colitis in active phase of left-sided or extensive UC. This would be used as add-on therapy to 5-ASA containing drugs in patients who are non-responders to 5-ASA therapy. The full 4 week therapy cycle must be prescribed by secondary care.

  budesonide Specialist knowledge/initiation NICE TA708
JPG decision

October 2019 - The Joint Prescribing Group approved the use of Jorveza (orodispersible budesonide) for the treatment of eosinophilic oesophagitis. 

  • Formulary status: Hospital only 
  • Jorveza® should only be prescribed in patients who have failed to respond to (or unable to have) a proton pump inhibitor, swallowed fluticasone and food elimination diet.
  • The full 12-week course is to be supplied by secondary care via an outpatient prescription.

NICE also published a TA in June 2021 and recommended the use of budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis.

  Modified-release tablet
Cortiment (Ferring Pharmaceuticals Ltd) Specialist knowledge/initiation
  Gastro-resistant capsule
Budenofalk (Dr. Falk Pharma UK Ltd) Specialist knowledge/initiation
  Gastro-resistant granules
Budenofalk (Dr. Falk Pharma UK Ltd) Specialist knowledge/initiation
  ciclosporin Shared care guideline NICE TA369
A formal Shared Care Guideline (SCG) may be available

Happy to prescribe

If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. 

Unhappy to prescribe

If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. 

  Oral solution
Neoral (Novartis Pharmaceuticals UK Ltd) Shared care guideline
A formal Shared Care Guideline (SCG) may be available

Happy to prescribe

If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. 

Unhappy to prescribe

If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. 

Sandimmun (Novartis Pharmaceuticals UK Ltd) Shared care guideline
A formal Shared Care Guideline (SCG) may be available

Happy to prescribe

If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. 

Unhappy to prescribe

If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. 

  Solution for infusion
Sandimmun (Novartis Pharmaceuticals UK Ltd) Hospital only
  filgotinib Hospital only NICE TA676
NICE TA792
  Oral tablet
Jyseleca (Galapagos Biotech Ltd) Hospital only
  golimumab Hospital only NICE TA220
NICE TA375
NICE TA225
NICE TA383
NICE TA497
NICE TA329
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  Solution for injection
Simponi (Merck Sharp & Dohme (UK) Ltd) Hospital only
  hydrocortisone Specialist knowledge/initiation
  infliximab Hospital only NICE TA134
NICE TA195
NICE TA375
NICE TA715
NICE TA199
NICE TA187
NICE TA163
NICE TA329
NICE TA383
Biosimilar

Remsima® (biosimilar infliximab) is the formulary choice brand for infliximab.

Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  Solution for injection
Remsima (Celltrion Healthcare UK Ltd) Hospital only
  mercaptopurine Shared care guideline
A formal Shared Care Guideline (SCG) may be available

Happy to prescribe

If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. 

Unhappy to prescribe

If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. 

  mesalazine Specialist knowledge/initiation
  Modified-release tablet
Mezavant XL (Takeda UK Ltd) Specialist knowledge/initiation
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

Pentasa (Ferring Pharmaceuticals Ltd) Specialist knowledge/initiation
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Gastro-resistant tablet
Octasa MR (Tillotts Pharma UK Ltd) Specialist knowledge/initiation
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

Salofalk (Dr. Falk Pharma UK Ltd) Specialist knowledge/initiation
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Modified-release granules
Pentasa (Ferring Pharmaceuticals Ltd) Specialist knowledge/initiation
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

Salofalk (Dr. Falk Pharma UK Ltd) Specialist knowledge/initiation
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Suppository
Pentasa (Ferring Pharmaceuticals Ltd) Specialist knowledge/initiation
Salofalk (Dr. Falk Pharma UK Ltd) Specialist knowledge/initiation
  methotrexate Shared care guideline
A formal Shared Care Guideline (SCG) may be available

Happy to prescribe

If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. 

Unhappy to prescribe

If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. 

  Oral solution
Methotrexate (Non-proprietary) Shared care guideline
A formal Shared Care Guideline (SCG) may be available

Happy to prescribe

If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. 

Unhappy to prescribe

If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. 

  Solution for injection
Methotrexate (Non-proprietary) Hospital only
Metoject PEN (medac UK) Hospital only
Nordimet (Nordic Pharma Ltd) Hospital only
Zlatal (Nordic Pharma Ltd) Hospital only
  Solution for infusion
Methotrexate (Non-proprietary) Hospital only
  mirikizumab Hospital only NICE TA925
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  Solution for injection
Omvoh (Eli Lilly and Company Ltd) Hospital only
  Solution for infusion
Omvoh (Eli Lilly and Company Ltd) Hospital only
  olsalazine sodium Hospital only
  ozanimod Hospital only NICE TA706
NICE TA828
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  Oral capsule
Zeposia (Bristol-Myers Squibb Pharmaceuticals Ltd) Hospital only
  prednisolone Joint formulary choice
  Gastro-resistant tablet
Prednisolone (Non-proprietary) Not approved for prescribing
Dilacort (Crescent Pharma Ltd) Not approved for prescribing
  Oral solution
Prednisolone (Non-proprietary) Joint formulary choice
  Suppository
Prednisolone (Non-proprietary) Joint formulary choice
  risankizumab Hospital only NICE TA596
NICE TA803
NICE TA888
  Solution for infusion
Skyrizi (AbbVie Ltd) Hospital only
  sulfasalazine Shared care guideline
A formal Shared Care Guideline (SCG) may be available

Happy to prescribe

If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. 

Unhappy to prescribe

If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. 

  Gastro-resistant tablet
Sulfasalazine (Non-proprietary) Shared care guideline
A formal Shared Care Guideline (SCG) may be available

Happy to prescribe

If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. 

Unhappy to prescribe

If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. 

Salazopyrin EN (Pfizer Ltd) Shared care guideline
A formal Shared Care Guideline (SCG) may be available

Happy to prescribe

If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. 

Unhappy to prescribe

If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. 

  Oral suspension
Sulfasalazine (Non-proprietary) Shared care guideline
A formal Shared Care Guideline (SCG) may be available

Happy to prescribe

If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. 

Unhappy to prescribe

If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. 

  Suppository
Salazopyrin (Pfizer Ltd) Shared care guideline
A formal Shared Care Guideline (SCG) may be available

Happy to prescribe

If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. 

Unhappy to prescribe

If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. 

  tofacitinib Hospital only NICE TA480
NICE TA543
NICE TA920
NICE TA547
  Modified-release tablet
Xeljanz (Pfizer Ltd) Hospital only
  Oral tablet
Xeljanz (Pfizer Ltd) Hospital only
  upadacitinib Hospital only NICE TA665
NICE TA744
NICE TA768
NICE TA829
NICE TA861
NICE TA814
NICE TA856
NICE TA905
North East London Formulary & Pathways Group’s Decision - Upadacitinib for Crohn's disease

April 2023 - The North East London Formulary & Pathways Group (FPG) approved the use of Upadicitinib for the treatment of Crohn's disease under a Free of Charge Scheme. This indication is currently under review by NICE - FPG decision will be reviewed upon publication of the NICE Technology Appraisal. 

  Modified-release tablet
Rinvoq (AbbVie Ltd) Hospital only
  ustekinumab Hospital only NICE TA180
NICE TA340
NICE TA456
NICE TA633
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  Solution for injection
Stelara (Janssen-Cilag Ltd) Hospital only
  Solution for infusion
Stelara (Janssen-Cilag Ltd) Hospital only
  vedolizumab Hospital only NICE TA352
NICE TA342
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

Where negative or terminated NICE Technology Appraisal(s) apply to this medicine

This medicine is not recommended for use for the indication(s) specified in the relevant NICE Technology Appraisal(s) as currently NICE cannot recommend its use.

  Solution for injection
Entyvio (Takeda UK Ltd) Hospital only
  Powder for solution for infusion
Entyvio (Takeda UK Ltd) Hospital only
Gastro-intestinal system / Irritable bowel syndrome
  alverine citrate Joint formulary choice
  linaclotide Joint formulary choice
  mebeverine hydrochloride Joint formulary choice
  Modified-release capsule
Mebeverine hydrochloride (Non-proprietary) Joint formulary choice
Aurobeverine MR (Milpharm Ltd) Joint formulary choice
Colofac MR (Viatris UK Healthcare Ltd) Joint formulary choice
  Oral suspension
Mebeverine hydrochloride (Non-proprietary) Not approved for prescribing
  mebeverine with ispaghula husk Not approved for prescribing
  Effervescent granules
Fybogel Mebeverine (Reckitt Benckiser Healthcare (UK) Ltd) Not approved for prescribing
  peppermint oil Joint formulary choice
  Modified-release capsule
Colpermin (Johnson & Johnson Ltd) Joint formulary choice
  Gastro-resistant capsule
Peppermint oil (Non-proprietary) Joint formulary choice
Colomint (Ambe Ltd) Joint formulary choice
Mintec (Almirall Ltd) Joint formulary choice
PepperMinn (Essential-Healthcare Ltd) Joint formulary choice
Gastro-intestinal system / Short bowel syndrome
  cimetidine Not approved for prescribing
  Oral solution
Cimetidine (Non-proprietary) Not approved for prescribing
Tagamet (Rosemont Pharmaceuticals Ltd) Not approved for prescribing
  teduglutide Non-formulary at HHFT and not suitable for primary care prescribing NICE TA804
Where negative or terminated NICE Technology Appraisal(s) apply to this medicine

This medicine is not recommended for use for the indication(s) specified in the relevant NICE Technology Appraisal(s) as currently NICE cannot recommend its use.

  Powder and solvent for solution for injection
Revestive (Takeda UK Ltd) Non-formulary at HHFT and not suitable for primary care prescribing
Gastro-intestinal system / Food allergy
  chlorphenamine maleate Joint formulary choice
  Oral solution
Chlorphenamine maleate (Non-proprietary) Joint formulary choice
Allerief (Crescent Pharma Ltd) Joint formulary choice
Piriton (Haleon UK Ltd) Joint formulary choice
  Solution for injection
Chlorphenamine maleate (Non-proprietary) Hospital only
  Oral tablet
Chlorphenamine maleate (Non-proprietary) Joint formulary choice
  sodium cromoglicate Not approved for prescribing
Gastro-intestinal system / Anal fissures
  glyceryl trinitrate Joint formulary choice
  Rectal ointment
Rectogesic (Kyowa Kirin International UK NewCo Ltd) Joint formulary choice
  lidocaine hydrochloride Not approved for prescribing
Gastro-intestinal system / Haemorrhoids
  benzyl benzoate with bismuth oxide, bismuth subgallate, hydrocortisone acetate, peru balsam and zinc oxide Joint formulary choice
  Suppository
Benzyl benzoate with bismuth oxide, bismuth subgallate, hydrocortisone acetate, peru balsam and zinc oxide (Non-proprietary) Joint formulary choice
  cinchocaine with hydrocortisone Joint formulary choice
  Suppository
Proctosedyl (Phoenix Labs Ltd) Joint formulary choice
Uniroid HC (Chemidex Pharma Ltd) Joint formulary choice
  cinchocaine with prednisolone Not approved for prescribing
  Suppository
Scheriproct (Karo Pharma UK Ltd) Not approved for prescribing
  hydrocortisone with lidocaine Joint formulary choice
  phenol Not approved for prescribing
  Solution for injection
Phenol (Non-proprietary) Not approved for prescribing
Gastro-intestinal system / Bowel cleansing
  bisacodyl Joint formulary choice
  Gastro-resistant tablet
Bisacodyl (Non-proprietary) Joint formulary choice
Dulco-Lax (Sanofi Consumer Healthcare) Not approved for prescribing
  Suppository
Dulco-Lax (Sanofi Consumer Healthcare) Not approved for prescribing
  docusate sodium Joint formulary choice
  Oral solution
Docusate sodium (Non-proprietary) Joint formulary choice
Docusol (Typharm Ltd) Joint formulary choice
  macrogol 3350 with anhydrous sodium sulfate, ascorbic acid, potassium chloride, sodium ascorbate and sodium chloride Hospital only
  Form unstated
Moviprep (Forum Health Products Ltd) Hospital only
Plenvu (Forum Health Products Ltd) Hospital only
  macrogol 3350 with anhydrous sodium sulfate, potassium chloride, sodium bicarbonate and sodium chloride Hospital only
  magnesium citrate with sodium picosulfate Hospital only
  magnesium sulfate Not approved for prescribing
Gastro-intestinal system / Constipation
  arachis oil Hospital only
  bisacodyl Joint formulary choice
  Gastro-resistant tablet
Bisacodyl (Non-proprietary) Joint formulary choice
Dulco-Lax (Sanofi Consumer Healthcare) Not approved for prescribing
  Suppository
Dulco-Lax (Sanofi Consumer Healthcare) Not approved for prescribing
  co-danthramer Specialist knowledge/initiation
  Oral suspension
Co-danthramer (Non-proprietary) Specialist knowledge/initiation
  co-danthrusate Not approved for prescribing
  Oral suspension
Co-danthrusate (Non-proprietary) Not approved for prescribing
  docusate sodium Joint formulary choice
  Oral solution
Docusate sodium (Non-proprietary) Joint formulary choice
Docusol (Typharm Ltd) Joint formulary choice
  glycerol Joint formulary choice
  Suppository
Glycerol (Non-proprietary) Joint formulary choice
  ispaghula husk Joint formulary choice
  Effervescent granules
Ispagel (Bristol Laboratories Ltd) Joint formulary choice
  lactulose Joint formulary choice
  Oral solution
Lactulose (Non-proprietary) Joint formulary choice
  liquid paraffin Not approved for prescribing
  Liquid
Liquid paraffin (Non-proprietary) Not approved for prescribing
  macrogol 3350 Joint formulary choice
  macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride Joint formulary choice
  Oral solution
Movicol (Forum Health Products Ltd) Joint formulary choice
  magnesium hydroxide Not approved for prescribing
  Oral suspension
Magnesium hydroxide (Non-proprietary) Not approved for prescribing
Phillips' Milk of Magnesia (Omega Pharma Ltd) Not approved for prescribing
  methylnaltrexone bromide Non-formulary at HHFT and not suitable for primary care prescribing
  Solution for injection
Relistor (Bausch & Lomb UK Ltd) Not approved for prescribing
  naldemedine Not approved for prescribing NICE TA651
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton University Hospital Foundation Trust does not provide the service

The Joint Prescribing Group (JPG) agreed not to approve this medicine for use at Homerton University Hospital Foundation Trust as the trust does not provide this service. The JPG recommends the funding of this medicine to enable it to be prescribed or initiated by other providers, provided it is used in accordance with the relevant NICE Technology Appraisal(s). 

  naloxegol Hospital only NICE TA345
  prucalopride Specialist knowledge/initiation NICE TA211
  senna Joint formulary choice
  Oral solution
Senokot (Reckitt Benckiser Healthcare (UK) Ltd) Joint formulary choice
  Oral tablet
Senokot (Reckitt Benckiser Healthcare (UK) Ltd) Joint formulary choice
  senna with ispaghula husk Not approved for prescribing
  sodium acid phosphate with sodium phosphate Specialist knowledge/initiation
Joint Prescribing Group's decision

The Joint Prescribing Group (JPG) agreed to approve the addition of Fleet Phospho-Soda® 24.4g/10.8g oral solution to the joint formulary as a booster bowel cleansing solution in patients undergoing Crohn's capsule endoscopy (July 2019) and colon capsule endoscopy for cancer screening (April 2021). 

Formulary status - Blue (hospital only)

  Oral solution
Fleet Phospho-soda (Recordati Pharmaceuticals Ltd) Not approved for prescribing
Joint Prescribing Group's decision

The Joint Prescribing Group (JPG) agreed to approve the addition of Fleet Phospho-Soda® 24.4g/10.8g oral solution to the joint formulary as a booster bowel cleansing solution in patients undergoing Crohn's capsule endoscopy (July 2019) and colon capsule endoscopy for cancer screening (April 2021). 

Formulary status - Blue (hospital only)

  Enema
Sodium acid phosphate with sodium phosphate (Non-proprietary) Specialist knowledge/initiation
Fleet Ready-to-use (Recordati Pharmaceuticals Ltd) Specialist knowledge/initiation
  sodium citrate Joint formulary choice
  sodium picosulfate Hospital only
  Oral solution
Sodium picosulfate (Non-proprietary) Not approved for prescribing
  sterculia Not approved for prescribing
  sterculia with frangula Not approved for prescribing
Gastro-intestinal system / Biliary disorders
  borneol with camphene, cineole, menthol, menthone and pinene Not approved for prescribing
  Gastro-resistant capsule
Rowachol (Meadow Laboratories Ltd) Not approved for prescribing
  chenodeoxycholic acid Non-formulary at HHFT and not suitable for primary care prescribing
  cholic acid Non-formulary at HHFT and not suitable for primary care prescribing
  colestyramine Joint formulary choice
  obeticholic acid Non-formulary at HHFT and not suitable for primary care prescribing NICE TA443
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service

This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service.

  ursodeoxycholic acid Specialist knowledge/initiation
  Oral suspension
Ursofalk (Dr. Falk Pharma UK Ltd) Specialist knowledge/initiation
Gastro-intestinal system / Hepatic encephalopathy
  lactulose Specialist knowledge/initiation
  Oral solution
Lactulose (Non-proprietary) Specialist knowledge/initiation
  rifaximin Specialist knowledge/initiation NICE TA337
Rifaximin not approved for 'small intestinal bacterial overgrowth'

September 2020 - the Joint Prescribing Group (JPG) declined the application for rifaximin to be used for small intestinal bacterial overgrowth.

Formulary status - Red (not approved for prescribing)

  Oral suspension
Rifaximin (Non-proprietary) Not approved for prescribing
Gastro-intestinal system / Oesophageal varices
  terlipressin acetate Hospital only
  Solution for injection
Terlipressin acetate (Non-proprietary) Hospital only
Glypressin (Ferring Pharmaceuticals Ltd) Hospital only
  vasopressin Hospital only
  Solution for injection
Vasopressin (Non-proprietary) Hospital only
Gastro-intestinal system / Obesity
  liraglutide Hospital only NICE TA664
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

Where negative or terminated NICE Technology Appraisal(s) apply to this medicine

This medicine is not recommended for use for the indication(s) specified in the relevant NICE Technology Appraisal(s) as currently NICE cannot recommend its use.

  Solution for injection
Saxenda (Novo Nordisk Ltd) Hospital only
Victoza (Novo Nordisk Ltd) Not approved for prescribing
  naltrexone with bupropion Not approved for prescribing NICE TA494
Where negative or terminated NICE Technology Appraisal(s) apply to this medicine

This medicine is not recommended for use for the indication(s) specified in the relevant NICE Technology Appraisal(s) as currently NICE cannot recommend its use.

  Modified-release tablet
Mysimba (Orexigen Therapeutics Ireland Ltd) Not approved for prescribing
  orlistat Joint formulary choice
  semaglutide Hospital only NICE TA875
  Solution for injection
Ozempic (Novo Nordisk Ltd) Not approved for prescribing
Wegovy FlexTouch (Novo Nordisk Ltd) Hospital only
Gastro-intestinal system / Diarrhoea
  co-phenotrope Not approved for prescribing
  codeine phosphate Not approved for prescribing
  Oral solution
Codeine phosphate (Non-proprietary) Not approved for prescribing
Galcodine (Thornton & Ross Ltd) Not approved for prescribing
  colesevelam hydrochloride Specialist knowledge/initiation
Joint Prescribing Group's decision

September 2020 - the Joint Prescribing Group (JPG) agreed to approve the addition of colesevelam to the joint formulary for the management of diarrhoea associated with bile acid malabsorption.

Product selection

Colestyramine light should be selected first line during the shortages of colestyramine.

Colesevalam has been added as a formulary option for use in patients who are already taking colestyramine, but are unable to access colestyramine or colestyramine light. The switching between these products is not equivalent and thus GPs needing to make this switch should seek specialist advice from HUHFT gastroenterology service. This can be via the GP email Advice & Guidance service.

Newly diagnosed patients with bile acid malabsorption requiring colesevalam should have treatment initiated by a gastroenterologist. Prescribing should be titrated in secondary care until symptom response, following which prescribing can be continued in the community.

  colestyramine Joint formulary choice
  kaolin with morphine Not approved for prescribing
  loperamide hydrochloride Joint formulary choice
  Orodispersible tablet
Imodium (McNeil Products Ltd) Not approved for prescribing
  Oral capsule
Loperamide hydrochloride (Non-proprietary) Joint formulary choice
  loperamide with simeticone Not approved for prescribing
Gastro-intestinal system / Gastro-intestinal smooth muscle spasm
  alverine citrate Joint formulary choice
  atropine sulfate Not approved for prescribing
  dicycloverine hydrochloride Joint formulary choice
  Oral solution
Dicycloverine hydrochloride (Non-proprietary) Joint formulary choice
  dicycloverine hydrochloride with aluminium hydroxide, magnesium oxide and simeticone Not approved for prescribing
  hyoscine butylbromide Joint formulary choice
  Solution for injection
Buscopan (Sanofi Consumer Healthcare) Non-formulary at HHFT and not suitable for primary care prescribing
  mebeverine hydrochloride Joint formulary choice
  Modified-release capsule
Mebeverine hydrochloride (Non-proprietary) Joint formulary choice
Aurobeverine MR (Milpharm Ltd) Joint formulary choice
Colofac MR (Viatris UK Healthcare Ltd) Joint formulary choice
  Oral suspension
Mebeverine hydrochloride (Non-proprietary) Not approved for prescribing
  propantheline bromide Hospital only
Gastro-intestinal system / Exocrine pancreatic insufficiency
  pancreatin Specialist knowledge/initiation
  Gastro-resistant capsule
Creon (Viatris UK Healthcare Ltd) Specialist knowledge/initiation
Nutrizym (Zentiva Pharma UK Ltd) Specialist knowledge/initiation
  Gastro-resistant granules
Creon (Viatris UK Healthcare Ltd) Specialist knowledge/initiation
Gastro-intestinal system / Dyspepsia
  alginic acid Joint formulary choice
  co-magaldrox Joint formulary choice
  Oral suspension
Mucogel (Rosemont Pharmaceuticals Ltd) Joint formulary choice
  co-simalcite Not approved for prescribing
  magnesium carbonate Not approved for prescribing
  magnesium trisilicate Not approved for prescribing
  magnesium trisilicate with magnesium carbonate and sodium bicarbonate Not approved for prescribing
  Oral suspension
Magnesium trisilicate with magnesium carbonate and sodium bicarbonate (Non-proprietary) Not approved for prescribing
  simeticone Hospital only
  Oral suspension
Infacol (Teva UK Ltd) Hospital only
  Oral drops
Dentinox Infant (Dendron Brands Ltd) Not approved for prescribing
  simeticone with aluminium hydroxide and magnesium hydroxide Not approved for prescribing
  Oral suspension
Maalox Plus (Sanofi Consumer Healthcare) Not approved for prescribing
  sodium alginate with potassium bicarbonate Joint formulary choice
  Oral suspension
Acidex Advance (Wockhardt UK Ltd) Not approved for prescribing
Gaviscon Advance (Reckitt Benckiser Healthcare (UK) Ltd) Joint formulary choice
Gastro-intestinal system / Gastric and duodenal ulceration
  cimetidine Not approved for prescribing
  Oral solution
Cimetidine (Non-proprietary) Not approved for prescribing
Tagamet (Rosemont Pharmaceuticals Ltd) Not approved for prescribing
  esomeprazole Joint formulary choice
Injection/infusion formulations

The injection/infusion formulation of this medicine is not recommended for prescribing in primary care (i.e. hospital only prescribing).

  Gastro-resistant tablet
Esomeprazole (Non-proprietary) Joint formulary choice
Nexium (Grunenthal Ltd, Haleon UK Ltd) Joint formulary choice
  Gastro-resistant capsule
Esomeprazole (Non-proprietary) Joint formulary choice
Emozul (Krka UK Ltd) Joint formulary choice
  Gastro-resistant granules
Nexium (Grunenthal Ltd) Joint formulary choice
  Powder for solution for injection
Esomeprazole (Non-proprietary) Hospital only
Nexium (Grunenthal Ltd) Hospital only
  famotidine Not approved for prescribing
  lansoprazole Joint formulary choice
  Orodispersible tablet
Lansoprazole (Non-proprietary) Joint formulary choice
Zoton FasTab (Pfizer Ltd) Joint formulary choice
  Gastro-resistant capsule
Lansoprazole (Non-proprietary) Joint formulary choice
  misoprostol Not approved for prescribing
  nizatidine Not approved for prescribing
  omeprazole Joint formulary choice
Injection/infusion formulations

The injection/infusion formulation of this medicine is not recommended for prescribing in primary care (i.e. hospital only prescribing).

  Gastro-resistant tablet
Omeprazole (Non-proprietary) Joint formulary choice
Losec MUPS (Neon Healthcare Ltd) Joint formulary choice
Mezzopram (Sandoz Ltd) Joint formulary choice
  Gastro-resistant capsule
Omeprazole (Non-proprietary) Joint formulary choice
Losec (Neon Healthcare Ltd) Joint formulary choice
  pantoprazole Joint formulary choice
Injection/infusion formulations

The injection/infusion formulation of this medicine is not recommended for prescribing in primary care (i.e. hospital only prescribing).

  Gastro-resistant tablet
Pantoprazole (Non-proprietary) Joint formulary choice
  Powder for solution for injection
Pantoprazole (Non-proprietary) Hospital only
Protium (Takeda UK Ltd) Hospital only
  rabeprazole sodium Joint formulary choice
  Gastro-resistant tablet
Rabeprazole sodium (Non-proprietary) Joint formulary choice
Pariet (Eisai Ltd) Not approved for prescribing
  ranitidine Joint formulary choice
Injection/infusion formulations

The injection/infusion formulation of this medicine is not recommended for prescribing in primary care (i.e. hospital only prescribing).

  sucralfate Specialist knowledge/initiation
Gastro-intestinal system / Gastro-oesophageal reflux disease
  cimetidine Not approved for prescribing
  Oral solution
Cimetidine (Non-proprietary) Not approved for prescribing
Tagamet (Rosemont Pharmaceuticals Ltd) Not approved for prescribing
  esomeprazole Joint formulary choice
  Gastro-resistant tablet
Esomeprazole (Non-proprietary) Joint formulary choice
Nexium (Grunenthal Ltd, Haleon UK Ltd) Joint formulary choice
  Gastro-resistant capsule
Esomeprazole (Non-proprietary) Joint formulary choice
Emozul (Krka UK Ltd) Joint formulary choice
  Gastro-resistant granules
Nexium (Grunenthal Ltd) Joint formulary choice
  Powder for solution for injection
Esomeprazole (Non-proprietary) Hospital only
Nexium (Grunenthal Ltd) Hospital only
  famotidine Not approved for prescribing
  lansoprazole Joint formulary choice
  Orodispersible tablet
Lansoprazole (Non-proprietary) Joint formulary choice
Zoton FasTab (Pfizer Ltd) Joint formulary choice
  Gastro-resistant capsule
Lansoprazole (Non-proprietary) Joint formulary choice
  nizatidine Not approved for prescribing
  omeprazole Joint formulary choice
  Gastro-resistant tablet
Omeprazole (Non-proprietary) Joint formulary choice
Losec MUPS (Neon Healthcare Ltd) Joint formulary choice
Mezzopram (Sandoz Ltd) Joint formulary choice
  Gastro-resistant capsule
Omeprazole (Non-proprietary) Joint formulary choice
Losec (Neon Healthcare Ltd) Joint formulary choice
  pantoprazole Joint formulary choice
  Gastro-resistant tablet
Pantoprazole (Non-proprietary) Joint formulary choice
  Powder for solution for injection
Pantoprazole (Non-proprietary) Hospital only
Protium (Takeda UK Ltd) Hospital only
  rabeprazole sodium Joint formulary choice
  Gastro-resistant tablet
Rabeprazole sodium (Non-proprietary) Joint formulary choice
Pariet (Eisai Ltd) Not approved for prescribing
  sodium alginate with calcium carbonate and sodium bicarbonate Joint formulary choice
  Oral suspension
Sodium alginate with calcium carbonate and sodium bicarbonate (Non-proprietary) Joint formulary choice
Acidex (Pinewood Healthcare) Not approved for prescribing
Gaviscon (Reckitt Benckiser Healthcare (UK) Ltd) Joint formulary choice
Gaviscon Liquid Relief (Reckitt Benckiser Healthcare (UK) Ltd) Joint formulary choice
Peptac (Teva UK Ltd) Joint formulary choice